Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer

被引：118

作者：

Naume, Bjorn ^{[2
]}

Zhao, Xi ^{[1
]}

Synnestvedt, Marit ^{[2
]}

Borgen, Elin ^{[3
]}

Russnes, Hege Giercksky ^{[3
]}

Lingjaerde, Ole Christian ^{[4
]}

Stromberg, Maria ^{[1
]}

Wiedswang, Gro ^{[5
]}

Kvalheim, Gunnar ^{[6
]}

Karesen, Rolf ^{[5
]}

Nesland, Jahn M. ^{[3
,7
]}

Borresen-Dale, Anne-Lise ^{[1
,7
]}

Sorlie, Therese ^{[1
,4
]}

机构：

[1] Natl Hosp Norway, Radiumhosp, Med Ctr, Inst Canc Res,Dept Genet, N-0310 Oslo, Norway

[2] Natl Hosp Norway, Radiumhosp, Med Ctr, Canc Clin, N-0310 Oslo, Norway

[3] Natl Hosp Norway, Radiumhosp, Med Ctr, Pathol Clin, N-0310 Oslo, Norway

[4] Univ Oslo, Fac Math & Nat Sci, Inst Informat, N-0316 Oslo, Norway

[5] Ullevaal Univ Hosp, Dept Surg, Oslo, Norway

[6] Natl Hosp Norway, Radiumhosp, Med Ctr, Canc Clin,Lab Cellular Therapy, N-0310 Oslo, Norway

[7] Univ Oslo, Fac Med, N-0316 Oslo, Norway

来源：

MOLECULAR ONCOLOGY | 2007年 / 1卷 / 02期

关键词：

DNA microarrays; Breast cancer; Micrometastases in bone marrow; Molecular subtypes; Clinical outcome;

D O I：

10.1016/j.molonc.2007.03.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Expression profiles of primary breast tumors were investigated in relation to disseminated tumor cells (DTCs) in bone marrow (BM) in order to increase our understanding of the dissemination process. Tumors were classified into five pre-defined molecular subtypes, and presence of DTC identified (at median 85 months follow-up) a subgroup of luminal A patients with particular poor outcome (p = 0.008). This was not apparent for other tumor subtypes. Gene expression profiles associated with DTC and with systemic relapse for luminal A patients were identified. This study suggests that DTC in BM differentially distinguishes clinical outcome in patients with luminal A type tumors and that DTC-associated gene expression analysis may identify genes of potential importance in tumor dissemination. (C) 2007 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

引用

页码：160 / 171

页数：12

共 51 条

[1] Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients [J].

Aas, T ;

Borresen, AL ;

Geisler, S ;

SmithSorensen, B ;

Johnsen, H ;

Varhaug, JE ;

Akslen, LA ;

Lonning, PE .

NATURE MEDICINE, 1996, 2 (07) :811-814

[2] Prospective identification of tumorigenic breast cancer cells [J].

Al-Hajj, M ;

Wicha, MS ;

Benito-Hernandez, A ;

Morrison, SJ ;

Clarke, MF .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988

[3] Prognostic relevance of gene amplifications and coamplifications in breast cancer [J].

Al-Kuraya, K ;

Schraml, P ;

Torhorst, J ;

Tapia, C ;

Zaharieva, B ;

Novotny, H ;

Spichtin, H ;

Maurer, R ;

Mirlacher, M ;

Köchli, O ;

Zuber, M ;

Dieterich, H ;

Mross, F ;

Wilber, K ;

Simon, R ;

Sauter, G .

CANCER RESEARCH, 2004, 64 (23) :8534-8540

[4] Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF [J].

Andersson, J ;

Larsson, L ;

Klaar, S ;

Holmberg, L ;

Nilsson, J ;

Inganäs, M ;

Carlsson, G ;

Öhd, J ;

Rudenstam, CM ;

Gustavsson, B ;

Bergh, J .

ANNALS OF ONCOLOGY, 2005, 16 (05) :743-748

[5] Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer [J].

Ayers, M ;

Symmans, WF ;

Stec, J ;

Damokosh, AI ;

Clark, E ;

Hess, K ;

Lecocke, M ;

Metivier, J ;

Booser, D ;

Ibrahim, N ;

Valero, V ;

Royce, M ;

Arun, B ;

Whitman, G ;

Ross, J ;

Sneige, N ;

Hortobagyi, GN ;

Pusztai, L .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (12) :2284-2293

[6] Metastasis genes: A progression puzzle [J].

Bernards, R ;

Weinberg, RA .

NATURE, 2002, 418 (6900) :823-823

[7] Gene expression profiling identifies molecular subtypes of inflammatory breast cancer [J].

Bertucci, F ;

Finetti, P ;

Rougemont, J ;

Charafe-Jauffret, E ;

Cervera, N ;

Tarpin, C ;

Nguyen, C ;

Xerri, L ;

Houlgatte, M ;

Jacquemier, J ;

Viens, P ;

Birnbaum, D .

CANCER RESEARCH, 2005, 65 (06) :2170-2178

[8] Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells [J].

Borgen, E ;

Naume, B ;

Nesland, JM ;

Kvalheim, G ;

Beiske, K ;

Fodstad, O ;

Diel, I ;

Solomayer, EF ;

Theocharous, P ;

Coombes, RC ;

Smith, BM ;

Wunder, E ;

Marolleau, JP ;

Garcia, J ;

Pantel, K .

CYTOTHERAPY, 1999, 1 (05) :377-388

[9] Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. [J].

Braun, S ;

Pantel, K ;

Muller, P ;

Janni, W ;

Hepp, F ;

Kentenich, CRM ;

Gastroph, S ;

Wischnik, A ;

Dimpfl, T ;

Kindermann, G ;

Riethmuller, G ;

Schlimok, G .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (08) :525-533

[10] A pooled analysis of bone marrow micrometastasis in breast cancer [J].

Braun, S ;

Vogl, FD ;

Naume, B ;

Janni, W ;

Osborne, MP ;

Coombes, RC ;

Schlimok, G ;

Diel, IJ ;

Gerber, B ;

Gebauer, G ;

Pierga, JY ;

Marth, C ;

Oruzio, D ;

Wiedswang, G ;

Solomayer, EF ;

Kundt, G ;

Strobl, B ;

Fehm, T ;

Wong, GYC ;

Bliss, J ;

Vincent-Salomon, A ;

Pantel, K .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (08) :793-802

← 1 2 3 4 5 6 →